My research focus is to investigate and define the biological role of Ref-1 in relapsed, drug-refractory childhood ALL. My ultimate goal is to translate lab findings from pre-clinical studies into Phase-I/II clinical trials in refractory or recurrent pediatric ALL. As a collaborator, I will be the lead clinical investigator responsible for obtaining IRB approvals, informed consents, collection of biological samples and analyzing clinical data.
Expertise: Pediatric Leukemias, clinical trials involving new agents.
